Reported Q: Q3 2025 Rev YoY: -8.1% EPS YoY: +468.3% Move: +3.71%
The Clorox Company
CLX
$125.95 3.71%
Exchange NYSE Sector Consumer Defensive Industry Household Personal Products
Q3 2025
Published: May 5, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for CLX

Reported

Report Date

May 5, 2025

Quarter Q3 2025

Revenue

1.67B

YoY: -8.1%

EPS

1.50

YoY: +468.3%

Market Move

+3.71%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $1.67B down 8.1% year-over-year
  • EPS of $1.50 increased by 468.3% from previous year
  • Gross margin of 44.6%
  • Net income of 186.00M
  • "“We held overall market shares and delivered our 10th consecutive quarter of gross margin expansion, which enables us to keep reinvesting in our brands, our innovation pipeline, and in the transformation of our business.”" - Linda Rendle
CLX
Company CLX

Executive Summary

The Clorox Company delivered a defensible QQ3 2025 performance in a challenging consumer environment. Revenue for Q3 2025 was $1.667B, down 8.1% YoY and 1.1% QoQ, while gross margin expanded to 44.6% (vs. prior-year 46.1% gross margin on a reported basis for the quarter’s mix), contributing to an operating income of $450M and net income of $186M (EPS $1.51). The company has now posted 10 consecutive quarters of gross margin expansion, underscoring its ability to reinvest in brands, innovation, and the broader transformation agenda despite near-term category softness. Management highlighted that the softness is largely macro-driven and concentrated in a volatile shopping environment, with household essentials remaining relatively resilient and consumers preserving at-home use and essential purchases.

Key drivers and forward-looking dynamics cited by management and reflected in the call and filings include: (i) tariff exposure with an estimated 12-month run-rate impact of about $100M, with Q4 headwinds of $10–$20M as inventory work-through unfolds, and mitigations including sourcing diversification, product reformulation, and targeted pricing; (ii) a gradual ERP transition expected to unlock capabilities and efficiencies, with retailers building inventory ahead of the go-live and a material unwind anticipated in H1 FY2026; (iii) a continued long-term algorithm of 3–5% organic sales growth, contingent on category normalization back toward mid-to-high single-digit growth trajectories in normalized conditions; (iv) near-term category volatility and retailer destocking, particularly in the Household segment, with limited impact on consumer in-stock and no wholesale shift away from at-home essentials; and (v) a constructive portfolio mix that supports premium pricing under value-based bundling while maintaining broad distribution across mass, club, and e-commerce channels.

Overall, Clorox remains well-positioned to sustain margin expansion and earnings growth through 2025 and beyond, supported by price-pack architecture, a diversified product portfolio, and a disciplined approach to capital allocation (dividends, buybacks, and selective divestitures). The near-term risks center on macro-driven demand weakness, tariff costs, ERP execution, and potential retailer inventory dynamics, all of which investors should monitor as the ERP transition nears completion and macro uncertainties evolve.

Key Performance Indicators

Revenue
Decreasing
1.67B
QoQ: -1.07% | YoY: -8.05%
Gross Profit
Decreasing
744.00M
44.60% margin
QoQ: 0.81% | YoY: -2.87%
Operating Income
Increasing
450.00M
QoQ: 94.81% | YoY: 92.31%
Net Income
Increasing
186.00M
QoQ: -3.63% | YoY: 464.71%
EPS
Increasing
1.51
QoQ: -2.58% | YoY: 468.29%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 1,673.00 1.29 -5.1% View
Q1 2026 1,429.00 0.65 -24.9% View
Q3 2025 1,668.00 1.50 -8.1% View
Q2 2025 1,686.00 1.54 -15.3% View
Q1 2025 1,762.00 0.79 +27.1% View